BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38238287)

  • 1. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
    Loscocco GG; Gesullo F; Capecchi G; Atanasio A; Maccari C; Mannelli F; Vannucchi AM; Guglielmelli P
    Blood Cancer J; 2024 Jan; 14(1):10. PubMed ID: 38238287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
    Gangat N; Karrar O; Al-Kali A; Begna KH; Elliott MA; Wolanskyj-Spinner AP; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
    Blood Cancer J; 2024 Jan; 14(1):11. PubMed ID: 38238303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
    Tefferi A; Vannucchi AM; Barbui T
    Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
    Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
    Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
    Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
    Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
    Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
    Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
    Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
    Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
    Sun C; Zhou X; Zou ZJ; Guo HF; Li JY; Qiao C
    Chin Med J (Engl); 2016 Aug; 129(15):1778-83. PubMed ID: 27453224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
    Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
    Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
    Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of Clinical Characteristics of
    Li YM; Yang EP; Wang ZQ; Wang DH; Niu JC; Li YJ; Ming J; Sun MQ; Chen Z; Liu WY; Lyu Y; Hu XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):197-201. PubMed ID: 38387921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
    Giraldo-Rincón AI; Naranjo Molina S; Gomez-Lopera N; Aguirre Acevedo D; Ucroz Benavidez A; Gálvez Cárdenas K; Cuellar Ambrosí F; Torres JD; Ospina S; Palacio K; Gaviria Jaramillo L; Muñeton CM; Vasquez Palacio G
    Colomb Med (Cali); 2023; 54(3):e2035353. PubMed ID: 38111518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.